Treatment(s) now being considered-Other - Page 2 of 3 Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Other Posts on Medivizor

Phase 3 clinical trial evaluating the safety and efficacy of adding everolimus to exemestane therapy in patients with hormone receptor-positive advanced breast cancer

Phase 3 clinical trial evaluating the safety and efficacy of adding everolimus to exemestane therapy in patients with hormone receptor-positive advanced breast cancer

Posted by on Jun 1, 2013 in Breast cancer | 0 comments

In a nutshell This phase 3 clinical trial tested whether everolimus (a non-hormonal treatment) added to hormone therapy with exemestane improved survival in patients with advanced breast cancer (BCa).  Some background Some BCa are fueled by female sex hormones (estrogen or progesterone) that help them grow. These types of cancer are called...

Read More

Evaluating the benefits of laparoscopy in determining the extent of peritoneal carcinomatosis for patients with colorectal cancer

Evaluating the benefits of laparoscopy in determining the extent of peritoneal carcinomatosis for patients with colorectal cancer

Posted by on May 13, 2013 in Colorectal cancer | 0 comments

In a nutshell This article evaluated whether the use of a minimally invasive diagnostic technique called laparoscopy before surgery to treat peritoneal carcinomatosis improves the selection of patients who can benefit the most from treatment. The authors of the study found that laparoscopy can be used to select patients for whom surgery may be a...

Read More

Phase I trial to determine the safety of a new anti-cancer drug: PD 0332991

Phase I trial to determine the safety of a new anti-cancer drug: PD 0332991

Posted by on Mar 11, 2013 in Breast cancer | 0 comments

In a nutshell This article presents the results from the first human trial of PD 0332991, a new anti-cancer drug. The main objective of the study was to determine the safety and recommended dose for further testing. Results warrant further studies and revealed that neutropenia (low white cell count) was the main side effect. Some background Cells...

Read More

Regorafenib is a new drug for the treatment of metastatic colorectal cancer after failure of previous therapies

Posted by on Mar 10, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study evaluated the efficacy of a new drug, Regorafenib, for the treatment of refractory (progressing despite several lines of treatment) metastatic colorectal cancer (mCRC).  Some background Many of the patients with colorectal cancer do not present any symptoms in the early stages of the disease so the cancer...

Read More

Comparison of two surgical techniques for the treatment of pseudomyxoma peritonei

Comparison of two surgical techniques for the treatment of pseudomyxoma peritonei

Posted by on Mar 4, 2013 in Colorectal cancer | 1 comment

In a nutshell The present study compared the efficacy of two surgical techniques to treat pseudomyxoma peritonei (PMP): debulking and cytoreduction. Cytoreductive surgery achieved better surgical results and yielded higher 3- and 5-year survival rates, compared with debulking. Some background PMP is a rare condition caused by the production of...

Read More

Combined safety results of 4 clinical trials using sipuleucel-T in patients with prostate cancer

Combined safety results of 4 clinical trials using sipuleucel-T in patients with prostate cancer

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

In a nutshell The present study summarized the outcomes of four clinical trials assessing the side-effects reported with sipuleucel-T treatment in patients with prostate cancer. The combined results indicated that this drug is relatively safe with mostly mild to moderate, short-term, and reversible side-effects. Some background As of...

Read More